|
|
 |
|
Viewing report
|
|
|
|
Atypical Antipsychotics: Life-Cycle Management and Future Trends
Decision Resources, Inc, Dec 2006, Pages: 17
The $15 billion antipsychotics market will be hard hit by generics of nearly all the most frequently prescribed atypicals and by a dearth of breakthrough therapies in the pipeline. Overall market decline will be significant by 2015, but current market leaders are staking out new territories to defend their franchises.
Get the Answers You Need to Shape Your Strategy
At present, because all marketed atypicals (except clozapine) are expensive, cost is not generally a factor in a physician’s choice of agent. That will change when the patent for branded risperidone expires.
What factors do physicians consider in prescribing?
How will prescribing change when lower-cost generics are available?
How will payers respond to availability of generic risperidone?
Pending genericization and a less than robust pipeline threaten the historic growth of the antipsychotics marketplace.
What kind of sales are antipsychotics likely to generate in 2010? In 2015?
What is the outlook for emerging atypicals?
A variety of tactics are available to manufacturers of current and emerging atypicals. What specific strategies are companies pursuing?
Will today’s prominent players continue to lead the marketplace?
Scope
The current market: Key players, atypical antipsychotics, current market leaders, indications, sales, major markets.
Market outlook: Sales trends through 2015, key players, “new-generation” atypicals, genericization, reimbursement issues, declining markets.
Survival strategies: Life-cycle management, line extensions, new indications and patient populations
|
|
|
|
